Shingles Vaccine Market – By Product, By Vaccine Type – Global Forecast, 2025 to 2034

Shingles Vaccine Market Size

The global shingles vaccine market size was valued at USD 4.9 billion in 2024 and is expected to exhibit growth at a CAGR of 10.1% from 2025 to 2034. High market growth can be attributed to the rising geriatric population, favorable reimbursement policies, and growing awareness about shingles and their complications, among other contributing factors.
 

Shingles, or herpes zoster, is caused by the reactivation of the varicella-zoster virus and primarily affects individuals over the age of 50. The risk of shingles and its severe complications, including postherpetic neuralgia, increases significantly with age, making vaccination an important preventive measure for older adults. As the global population ages, demand for shingles vaccines is expected to rise to meet the needs of this vulnerable demographic.
 

Additionally, public health campaigns and educational initiatives have raised awareness of the health risks associated with shingles, particularly for older adults. Health organizations are actively working to inform people about the importance of vaccination in preventing shingles and reducing the likelihood of long-term pain. As a result, more people within the geriatric population, along with their caregivers, are opting for vaccination as a proactive health measure, fueling growth in the shingles vaccine market.
 

The shingles vaccine is an immunization specifically designed to prevent shingles, a painful skin rash caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. The vaccine works by boosting the body’s immune response to the virus, thereby reducing the likelihood of reactivation in older adults, who are more susceptible to shingles.
 

Shingles Vaccine Market Trends

New-generation vaccines, particularly recombinant shingles vaccines, offer high efficacy and have transformed the prevention landscape for herpes zoster (shingles), especially among older adults who are most vulnerable to this disease. Recent developments have addressed past limitations of traditional vaccines, including concerns about weakened immunity in aging populations and adverse effects.
 

• Recombinant shingles vaccines, such as Shingrix, represent a major advancement over earlier live-attenuated vaccines. These vaccines use targeted proteins from the varicella-zoster virus to stimulate immunity without the need for live viruses, making them suitable for individuals with weakened immune systems. Clinical trials have demonstrated that recombinant vaccines offer over 90% efficacy in preventing shingles, even among adults over 60, and have a lower likelihood of triggering adverse effects. This high level of efficacy and safety has led to increased recommendations from health organizations, encouraging more people to opt for vaccination.
   
• Additionally, advances in vaccine technology have resulted in longer-lasting immunity. Earlier shingles vaccines showed a decline in efficacy over time, necessitating consideration of additional doses or boosters. Recombinant vaccines, however, offer improved durability, providing extended protection that is critical for older adults, who may be at higher risk of developing shingles as their immune function naturally declines. This extended immunity reduces the need for frequent revaccination, adding convenience for patients and supporting stronger market demand.
   

Shingles Vaccine Market Analysis

Based on product, the market is classified into Shingrix, Zostavax, and SKYZoster. The Shingrix segment generated the highest revenue of USD 4.2 billion in 2024.
 

• Shingrix’s recombinant formulation provides robust and durable protection against shingles, which is especially beneficial for the aging population, who are at greater risk for the disease and its complications. Its effectiveness remains strong over time, reducing the need for additional doses, unlike older live-attenuated vaccines. This long-lasting immunity makes Shingrix a cost-effective solution, increasing its adoption rates globally.
   
• Leading health organizations, such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), strongly recommend Shingrix for adults over the age of 50, as well as for certain immune-compromised groups. These endorsements have driven higher vaccination rates, particularly in North America and Europe, where shingles prevention is widely prioritized.
   
• Additionally, since Shingrix does not contain a live virus, it is considered safe for individuals with weakened immune systems, who previously had limited options for shingles prevention. The safety and efficacy of Shingrix in these populations have expanded its recommended use, broadening the scope of shingles vaccination and further strengthening Shingrix’s market position.
   

Based on vaccine type, the shingles vaccine market is segmented into recombinant vaccine and live attenuated vaccine. The recombinant vaccine segment dominated the market in 2024 and is anticipated to reach USD 11.3 billion by the end of the forecast period.
 

• Recombinant shingles vaccines demonstrate over 90% efficacy, offering robust and long-lasting protection against shingles, even among high-risk populations. This strong and sustained immunity is essential for the aging demographic, as they are most susceptible to shingles and its severe complications. The longer duration of immunity provided by recombinant vaccines, compared to live attenuated vaccines, makes them a preferred choice, reducing the need for additional doses and follow-up.
   
• Additionally, pharmaceutical companies producing recombinant vaccines, such as GlaxoSmithKline with Shingrix, have expanded production and distribution networks globally, making recombinant vaccines widely accessible. Strategic partnerships with healthcare providers, pharmacies, and public health organizations have helped bring recombinant vaccines to a broad patient base, ensuring consistent availability and reinforcing their market dominance.
   

North America shingles vaccine market accounted for USD 2.7 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 9.6% between the 2025 to 2034.
 

• North America holds a significant share of the market, driven by high awareness of shingles prevention, favorable healthcare policies, and strong support from public health organizations. In the U.S., the Centers for Disease Control and Prevention (CDC) actively recommends shingles vaccination for adults aged 50 and older, leading to the widespread adoption of vaccines such as Shingrix.
   
• Additionally, healthcare insurance coverage for shingles vaccination under Medicare and other private insurance plans increases accessibility, making it easier for older adults to get vaccinated. With an aging population and proactive public health initiatives, North America continues to be a leading region in the market.
   

France shingles vaccine market is projected to grow remarkably in the coming years.
 

• French health authorities recognize the risks posed by shingles and its complications, particularly postherpetic neuralgia, which disproportionately affects older adults.
   
• The national healthcare system’s support for vaccination programs, including subsidies and insurance coverage, makes the vaccine accessible to a large portion of the target demographic.
   
• This strong support from the healthcare system, along with an aging population, contributes to France’s significant share in the European market.
   

Japan holds a dominant position in the Asia Pacific shingles vaccine market.
 

• With one of the highest proportions of elderly individuals globally, Japan faces a substantial public health challenge in managing shingles and its complications. To address this, healthcare authorities in Japan are increasingly promoting shingles vaccination for seniors.
   
• The Japanese government has implemented initiatives to increase vaccine awareness and expand coverage, making shingles vaccination more accessible through healthcare providers and public health programs. These efforts, combined with a proactive approach to elderly healthcare, contribute to Japan's substantial share in the market.
   

Shingles Vaccine Market Share

The market is highly competitive, with key players focusing on product innovation, strategic partnerships, and market expansion. GSK leads the market with its Shingrix vaccine, which has demonstrated superior efficacy in preventing shingles and its complications. Shingrix is widely recommended by health authorities, including the CDC, contributing to its strong market presence in North America and Europe. Merck is another major competitor with its Zostavax vaccine, which, although effective, has been largely replaced by Shingrix due to its higher efficacy. The market is characterized by strong competition between companies focused on enhancing vaccine accessibility, improving immunization rates, and expanding insurance coverage to reach a broader demographic.
 

Shingles Vaccine Market Companies

Prominent players operating in the shingles vaccine industry include:

• GSK plc
• Merck & Co.
• SK bioscience
   

Shingles Vaccine Industry News:

• In April 2023, GlaxoSmithKline Pharmaceuticals Ltd. (GSK) announced the launch of its shingles vaccine in India. This product launch helped the company to expand its customer base and generate enhanced revenue.
   
• In January 2023, SK bioscience announced that the company had received a biologics license application approval for the SKYZoster from the National Pharmaceutical Regulatory Agency (NPRA) in Malaysia. This strategy helped the company to gain a competitive edge over its peers.
   

The shingles vaccine market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Shingrix
• Zostavax
• SKYZoster

Market, By Vaccine Type

• Recombinant vaccine
• Live attenuated vaccine

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE